Publications by authors named "Thomas Haverty"

Claim this Profile
P
Phase 1 Renal Impairment Trial Results Supports Targeted Individualized Dosing of ELX-02 in Patients With Nephropathic Cystinosis.
Thomas Haverty, David J Wyatt, Kaela M Porter, Andi Leubitz, Kate Banks

J Clin Pharmacol· July 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Rebound eosinophilia after treatment of hypereosinophilic syndrome and eosinophilic gastroenteritis with monoclonal anti-IL-5 antibody SCH55700.
Yae-Jean Kim, Calman Prussin, Brian Martin, Melissa A Law, Thomas P Haverty

J Allergy Clin Immunol· December 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and efficacy of the monoclonal anti-interleukin-5 antibody SCH55700 in the treatment of patients with hypereosinophilic syndrome.
Amy D Klion, Melissa A Law, Pierre Noel, Yae-Jean Kim, Thomas P Haverty

Blood· April 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis